AXSM catalyst calendar

Axsome Therapeutics, Inc.

Upcoming catalysts
11
Cash runway
46.4 months
Cash & investments
$320M
Phase 3 programs
26

Axsome Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on October 19, 2026, a projected date rather than a confirmed one. There are 11 upcoming events on record.

Cash runway is approximately 46.4 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 22 concluded trials, 91% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
October 19, 2026 est. Next quarterly earnings (projected) Earnings —
December 15, 2026 Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN) Trial Milestone Phase 3
December 15, 2026 Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol Trial Milestone Phase 3
December 15, 2027 A Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge Eating Disorder Trial Milestone Phase 3
December 15, 2027 An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD Trial Milestone Phase 3
December 15, 2027 Studying NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT) Trial Milestone Phase 3
March 15, 2028 Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design Trial Milestone Phase 3
May 15, 2028 Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia Trial Milestone Phase 3
June 30, 2028 Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2) Trial Milestone Phase 3
June 30, 2028 Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3) Trial Milestone Phase 3
December 15, 2028 Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol Trial Milestone Phase 3

Track AXSM alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open AXSM in the tracker

Recent history

DateEventTypePhase
August 10, 2026 Quarterly results filed (8-K) Earnings —
July 15, 2026 8-K filed: Other event Filing —
June 9, 2026 8-K filed: Leadership change Corporate —
June 3, 2026 8-K filed: Other event Filing —
May 4, 2026 Quarterly results filed (8-K) Earnings —
April 30, 2026 8-K filed: Other event Filing —
April 1, 2026 8-K filed: Other event Filing —
March 15, 2026 A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms Trial Milestone Phase 4
February 23, 2026 Quarterly results filed (8-K) Earnings —
February 17, 2026 8-K filed: Other event Filing —
January 12, 2026 Quarterly results filed (8-K) Earnings —
December 31, 2025 8-K filed: Other event Filing —
November 3, 2025 Quarterly results filed (8-K) Earnings —
August 20, 2025 8-K filed: Other event Filing —
August 4, 2025 Quarterly results filed (8-K) Earnings —
June 10, 2025 8-K filed: Other event Filing —
June 9, 2025 8-K filed: Other event Filing —
May 27, 2025 8-K filed: Other event Filing —
May 13, 2025 8-K filed: Material agreement, Other event Corporate —
May 5, 2025 Quarterly results filed (8-K) Earnings —
February 17, 2025 An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study Trial Milestone Phase 3
February 7, 2025 A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS) Trial Milestone Phase 3
December 31, 2024 Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol Trial Milestone Phase 3
December 3, 2024 A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation Trial Milestone Phase 3
November 27, 2024 Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE) Trial Milestone Phase 3
November 21, 2024 A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation Trial Milestone Phase 3
November 15, 2024 A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE) Trial Milestone Phase 3
March 15, 2024 A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy Trial Milestone Phase 3
November 21, 2022 Assessing Clinical Outcomes in Alzheimer's Disease Agitation Trial Milestone Phase 3
September 19, 2022 Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study Trial Milestone Phase 4

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.